DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE)

Clinical trials for DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE) explained in plain language.

Never miss a new study

Get alerted when new DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE) trials appear

Sign up with your email to follow new studies for DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Lupus patients continue treatment in Follow-Up study

Disease control Recruiting now

This study allows patients with lupus who completed two previous trials to continue taking the medication deucravacitinib. The goal is to maintain disease control for those who benefited from the drug. Only 35 participants who finished the earlier studies are eligible to join.

Matched conditions: DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE)

Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE)

Get alerted when new DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE) trials appear

Lupus patients continue treatment in Follow-Up study